Gross Retention excludes expansion - it shows pure churn / contraction loss. The gap between NRR and GRR is the expansion lift.
Peak NRR of 173% in FY2021-Q3. Latest is 112% - that's -61pp from peak.
Doximity is above the Healthcare SaaS Public median by +0pp (cell median: 112%)
Doximity (DOCS) is a healthcare saas company at the public stage. As of its most recent disclosure (FY2026-Q3), Doximity reported a Net Revenue Retention rate of 112% - a mid-pack result for B2B SaaS at this segment.
Doximity's NRR peaked at 173% in FY2021-Q3, 61pp above today's level. Over the past three years, the metric has contracted by 55pp. The most recent quarter lost 6pp QoQ.
Within its peer set (healthcare saas companies at public stage in the $25k-$100k acv band), Doximity's NRR is roughly in line with the cell median of 112%. Compare against the full peer cell aggregate for distribution and top performers.
Contract shape and forward-booked revenue.
Health scores, usage, and time-to-value when disclosed.
Logo flow per period (count-side complement to dollar-based NRR).
Support tiers: free · premium · enterprise
CS team segments: Strategic · SMB
CSM model: account-named
Education programs: Inaugural Training Summit
Customer Advisory Board: Yes
Named CS initiatives across recent disclosures (newest first).
Launch and rollout of AI clinical reference and note-taking tools to health systems.
"over 100 of the top health systems in the country have now reviewed, cleared privacy... and ultimately bought our AI suite"
Multi-module integrated offerings that allow AI to optimize line items across newsfeed and workflow channels.
"Our multi-module integrated offerings... represented over 40% of bookings in Q2, compared to less than 5% last year."
Self-service portal for clients to track ROI, script lift, and manage programs in real-time.
"Our portal, in terms of number of quarterly active client users, is up 3x year-on-year."
HIPAA-compliant ambient note-taking tool launched to reduce physician administrative burden.
"Doximity AI Scribe, which launched last week... a HIPAA-compliant ambient note-taking tool."
Acquisition of AI clinical reference startup to integrate medical corpus into Doximity GPT.
"pleased to announce the acquisition of Pathway, a six-person, seven-year-old Montreal startup specializing in AI."
A single place for clients to test strategies and see ROI results using IQVIA data.
"Our client portal is weaving all of this together by providing our clients a single, trusted place to test strategies"
Custom-tailored dynamic approach for doctors across multiple modules.
"clients can leverage our data science to create a custom-tailored dynamic approach for each doctor."
Challenges acknowledged by management. Useful peer signals - your team is probably not alone.
Pharma client uncertainty regarding White House MFN agreements delayed budget releases and bookings.
"We saw this uncertainty continue through year-end, with 16 of the top 20 pharma companies signing Most Favored Nation agreements"
Uncertainty over how recent policy changes (D2C advertising, Trump admin) may influence annual budgets.
"client discussions suggest some uncertainty over how recent policy changes may influence annual budgets"
Regulatory reviews can delay program launches.
"integrated programs are allowing them to do that by starting with whatever module has content pre-approved."
Curated quotes about customer outcomes, retention, renewals.
"Our client portal is weaving all of this together by providing our clients a single, trusted place to test strategies and see their results."
"Our goal is always to help our customers get on channel as quickly as possible to maximize their ROI."
"Similar to prior quarters, our existing customers continue to lead our growth."
"With over 75% of Scribe users returning each and every week, we are thrilled to add another very sticky tool."
"With our earlier integrated program starts and our client portal insights, we have actually seen our customers have much more conviction in adding on to their programs sooner."
"The number of ROI studies we've been able to show them as a result is up over 10x what it was pre-portal. That just allows them, again, to see the value of their investments with us."
Side-by-side NRR, customer cohorts, commercial structure, and CS motion.
Doximity appears on 2 of our retention leaderboards.
Free to embed on your blog or board deck. Includes a small backlink to cust.co.
Or grab the data: JSON API →
| Period | NRR | GRR | Source type | Filing |
|---|---|---|---|---|
| FY2026-Q3 | 112% | - | 10-Q-mdna | source ↗ |
| FY2026-Q2 | 118% | - | 10-Q-mdna | source ↗ |
| FY2026-Q1 | 118% | - | 10-Q-mdna | source ↗ |
| FY2025-Q4 | 119% | - | earnings-call-transcript | source ↗ |
| FY2025-Q3 | 117% | - | 10-Q-mdna | source ↗ |
| FY2025-Q2 | 114% | - | 10-K | source ↗ |
| FY2025-Q1 | 114% | - | 10-Q-mdna | source ↗ |
| FY2024-Q2 | 114% | - | earnings-call-transcript | source ↗ |
| FY2024-Q1 | 117% | - | 10-K | source ↗ |
| FY2023-Q1 | 153% | - | 10-K | source ↗ |
| FY-2022 | 119% | - | 10-Q-mdna | source ↗ |
| FY2022-Q4 | 133% | - | 10-Q-mdna | source ↗ |
| FY2022-Q3 | 128% | - | 10-Q-mdna | source ↗ |
| FY2022-Q2 | 139% | - | 10-Q-mdna | source ↗ |
| FY2022-Q1 | 139% | - | 10-Q-mdna | source ↗ |
| FY-2021 | 117% | - | 10-Q-mdna | source ↗ |
| FY2021-Q3 | 173% | - | 10-Q-mdna | source ↗ |
| FY2021-Q2 | 167% | - | 10-Q-mdna | source ↗ |
Generate a live retention report against Doximity and your full peer cell. Ungated. Downloadable as PDF.